medigraphic.com
Revista Latinoamericana de Microbiología

2002, Número 2

<< Anterior Siguiente >>

Microbiología 2002; 44 (2)


Susceptibilidad a 5-Fluorocitosina, miconazol y anfotericina B de cepas de Candida albicans aisladas de la garganta de pacientes no infectados de SIDA

Paniagua CGL, Monroy PE, Negrete AE, Vaca PS

Idioma: Ingles.
Referencias bibliográficas: 19
Paginas: 65-68
Archivo PDF: 77.01 Kb.


RESUMEN

Se analizaron 80 cepas de Candida albicans, aisladas de las gargantas de pacientes que acudieron a la Clínica Universitaria de la Facultad de Estudios Superiores Iztacala de la Universidad Nacional Autónoma de México. Las cepas se identificaron por morfología colonial y microscópica, por formación de tubo germinativo y mediante auxanograma y zimograma. Las concentraciones mínimas inhibitorias (CMI) de 5-fluorocitosina, miconazol y anfotericina B se determinaron por microdilución en placa. La distribución de frecuencia de la CMI de 5-fluorocitosina mostró un solo pico (0.25-8.0 µg/ml), con 65% de cepas sensibles (CMI ≤ 1.0 µg/ml) y 35% de cepas con sensibilidad intermedia (CMI = 1.1-8 µg/ml). La distribución de frecuencia de la CMI de miconazol fue trimodal, con 6.25% cepas sensibles (CMI = 1.562 µg/ml), 48.75% con sensibilidad intermedia (CMI = 3.125-12.5 mg/ml) y 45% resistentes (CMI = 25-50 µg/ml). Todas las cepas fueron sensibles a anfotericina B (CMI = 0.0156-0.125 µg/ml). Estos resultados muestran que la anfotericina B fue el antimicótico más activo, seguido por la 5-fluorocitosina, contra las cepas de C. albicans estudiadas, y que el miconazol fue el menos efectivo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Anaissie, E.J., G.P. Bodey and M.G. Rinaldi. 1989. Emerging fungal pathogens. Eur. J. Clin. Microbiol. Infect. Dis. 8:323-330.

  2. Banerjee, S.N., T.G. Emori, D.H. Culver, R.P. Gaynes, W.R. Jarvis, T. Horan, J.R. Edwars, T. Tolson, T. Henderson and W.J. Marones. 1991. The National Nosocomial Infections Surveillance System. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am. J. Med. 91 (Suppl. 3B): 86S-89S.

  3. Barchiesi, F., A.L. Colombo, D.A. McGough, A.W. Fothergill, and M.G. Rinaldi. 1994. In vitro activity of new antifungal triazole, D0870, against Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 38:2553-2556.

  4. Batura-Gabryel, N., U. Wiezorec and W. Mlynaiczyk. 1997. In vitro susceptibility of antifungal agents of Candida strains isolated from patients with various diseases of the respiratory tract. Pneumonol. Alergol. Pol. 65: 355-359.

  5. Conly, J., R. Rennie, J. Johnson, S. Farah and L. Hellman. 1992. Disseminated candidiasis due to amphotericin B-resistant Candida albicans. J. Infect. Dis. 165:761-764.

  6. Dick, J., W. Merz and R. Sarai. 1980. Incidence of polyene resistant yeast recovered from clinical specimens. Antimicrob. Agents Chemother. 18:158-163.

  7. Drouhet, E. and B. Dupont. 1987. Evolution of antifungal agents: Past, present and future. Rev. Infect. Dis. 9 (suppl. 1): S4-S14.

  8. Fan-Harvard, P., D. Capano, S.M. Smith, A. Mangia and Eng R.H.K. 1991. Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy. Antimicrob. Agents Chemother. 35:2302-2305.

  9. Galgiani, J.N, D.J. Drutz, D.S. Feingold, T.M. Kerkering, L.R. McCarthy, M.A. Saubolle and J.C. Sherris. 1985. Committee report. Antifungal susceptibility testing. National Committee for Clinical Laboratory Standards. Villanova. Pa. 5:433-481.

  10. Gallis, R, R.H. Drew and W.W. Pickard. 1990. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12: 308-329.

  11. Hernández, M.L., C. Gil, J. Pla and C. Nombela. 1998. Induced expression of Candida albicans multidrug resistance gene CDR1 in response to fluconazole and other antifungals. Yeast 14:517-526.

  12. Law, D., C.B. Moore, H.M. Wardle, L.A. Ganguli, M.G. Keaney and D.W. Denning. 1994. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J. Antimicrob. Chemother. 34:659-668.

  13. Maksymiuk, A.W, S. Thongprasert, R. Hopfer, M. Luna, V. Fainstein and G.P. Bodey. 1984. Systemic candidiasis in cancer patients. Am. J. Med. 77: 20-27.

  14. Monteil, R.A., I. Madinier, and Y. Le Fichoux. 1997. In vitro antifungal resistance of oral Candida albicans strains in non-AIDS patients. Oral Microbiol. Immunol. 12: 126-128.

  15. Radetsky, M., R.C. Wheeler, M.M. Roe and J.K. Todd. 1986. Microtiter broth dilution method for yeast susceptibility testing with validation by clinical outcome. J. Clin. Microbiol. 24:600-606.

  16. Soll, D.R., R. Galask, J. Schmid, C. Hanna, H. Mac and B. Morrow. 1991. Genetic dissimilarity of commensal strains of Candida spp. Carried in different anatomical locations of the healthy women. J. Clin. Microbiol. 29: 1702-1710.

  17. Vazquez, J.A., M.T. Arganoza, D. Boikov, S. Yoon, J.D. Sobel and R.A. Akins.1998. Stable phenotypic resistance of Candida species to amphotericin B conferred by preexposure to subinhibitory levels of azoles. J. Clin. Microbiol. 36:2690-2695.

  18. White, T.C. 1997. Increased mRNA levels of ERG16, CDR and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents. Chemother. 41:1482-1487.

  19. Yoshida, T., K. Jono & K. Okonogi. 1997. Modified agar dilution susceptibility testing method for determining in vitro activities of antifungal agents, including azole compounds. Antimicrob. Agents Chemother. 41(6):1349-1351.




2020     |     www.medigraphic.com